Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Geneva Claims Fluoxetine 10 Mg Cap Exclusivity; Barr Restates Cipro Income

Executive Summary

Geneva is reclaiming sole rights to the generic exclusivity for the 10 mg capsule form of fluoxetine.

You may also be interested in...



Pfizer Estrostep Fe Is Barr's Next Patent Challenge; Ortho-Novum Trial By Oct.

Barr's patent challenge against Pfizer's Estrostep Fe is the generic company's latest step in attempting to expand its oral contraceptives franchise.

Pfizer Estrostep Fe Is Barr's Next Patent Challenge; Ortho-Novum Trial By Oct.

Barr's patent challenge against Pfizer's Estrostep Fe is the generic company's latest step in attempting to expand its oral contraceptives franchise.

Medicare Rx Benefit "More Significant" Than Waxman/Hatch Reform - Barr

Enactment of a Medicare prescription drug benefit is a higher priority for generic drug companies than reforms to the Waxman/Hatch Act, Barr CEO Bruce Downey told analysts Aug. 7.

Related Content

UsernamePublicRestriction

Register

PS037793

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel